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Rheumatoid arthritis and risk for 
Alzheimer’s disease: a systematic 
review and meta-analysis and a 
Mendelian Randomization study
Stefania Policicchio1,2, Aminah Noor Ahmad3, John Francis Powell1 & Petroula Proitsi1
Rheumatoid arthritis (RA) patients have been observed to be at a lower risk of developing Alzheimer’s 
Disease (AD). Clinical trials have showed no relationship between nonsteroidal anti-inflammatory drug 
(NSAID) use and AD. The aim of this study was to establish if there is a causal link between RA and 
AD. A systematic literature review on RA incidence and its link to AD was carried out according to the 
PRISMA guidelines. Eight case-control and two population-based studies were included in a random 
effects meta-analysis. The causal relationship between RA and AD was assessed using Mendelian 
Randomization (MR), using summary data from the largest RA and AD Genome Wide Association 
(GWA) and meta-analysis studies to date using a score of 62 RA risk SNPs (p < 5 * 10−8) as instrumental 
variable (IV). Meta-analysis of the literature showed that RA was associated with lower AD incidence 
(OR = 0.600, 95% CI 0.46–0.77, p = 1.03 * 10−4). On the contrary, MR analysis did not show any 
evidence of a causal association between RA and AD (OR = 1.012, 95% CI 0.98–1.04). Although there is 
epidemiological evidence for an association of RA with lower AD incidence, this association does not 
appear to be causal. Possible explanations for this discrepancy could include influence from confounding 
factors such as use of RA medication, selection bias and differential RA diagnosis.
Characterized by the development of amyloid plaques and neurofibrillary tangles in the brain, Alzheimer’s 
Disease (AD) is the most common type of dementia. It impairs an individual’s ability to carry out basic tasks such 
as bathing and eating. Cognitive function declines, and patients in late stages may be unable to recognize loved 
ones and become dependent on constant care. Ultimately, AD is fatal1.
Information transfer at the synaptic junctions of the brain is compromised in AD patients due to the accumu-
lation of extracellular beta amyloid, which also contributes to neuronal cell death. Inside the neurons, increased 
levels of tau, a protein that stabilizes microtubules, forms neurofibrillary tangles that block transport of nutrition 
and necessary molecules throughout the cell. This process also contributes to neuronal cell death1.
Pharmacological treatments of AD are limited, with current therapies improving symptoms only transiently. 
These include cholinesterase inhibitors such as donepezil and rivastigmine, in mild to moderate cases2, and 
memantadine, an NMDA receptor antagonist, in moderate to severe cases. Disease modifying treatments that 
affect the underlying AD pathogenesis are, as yet, unavailable. The optimal time to administer such treatments 
may be during the early stages of the pathophysiological process of the disease, before it is clinically apparent3.
Neuroinflammation has been linked to AD pathology, although the lack of pain fibers in the brain means the 
classic signs of inflammation, such as pain and swelling, are absent4. Astrocytes and microglia cluster at sites of 
amyloid beta deposits. Microglial expression of C/EBPβ, a protein that regulates pro-inflammatory molecules 
such as interleukin 6 (IL-6), interleukin 8 (IL-8), granulocyte colony-stimulating factor, tumour necrosis factor 
alpha (TNF-α), complement C3 and C-reactive protein (CRP), is significantly increased in the AD cortex com-
pared to the non AD cortex4. Additionally, astrocytes are thought to secrete many of the same pro-inflammatory 
molecules, although less is known about their role in inflammation in AD4. A study in which lipopolysaccharide 
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(LPS) was used to produce chronic neuroinflammation in rats reproduced some of the features of AD, such as 
working memory deficit, elevated levels of beta amyloid precursor protein, and temporal lobe pathology associ-
ated with cell loss5.
Neuroinflammation responses can be induced by both CNS-intrinsic factors and systemic influences6 and 
a number of conditions such as diabetes7, obesity8, atherosclerosis9, depression10, psoriasis11 and cardiovascu-
lar disease12, which have been proposed as risk factors for the development of AD are associated with chronic 
inflammation13.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation, destruction of 
bone and cartilage, and autoantibody production, causing progressive disability14. It also has systemic features, 
and frequently occurs with a variety of co-morbidities, some of which have significant effects on its outcome and 
have been linked to its inflammatory pathogenesis such as cardiovascular disease15–17, diabetes mellitus18,19 and 
depression20,21.
Paradoxically, RA, itself an inflammatory condition, which is also associated with risk factors for AD, is 
often considered a negative risk factor for the development of AD22. Although, overall the incidence of RA in 
AD patients has been found to be reduced23–30 compared to healthy controls, contradictory results have been 
reported, with some studies reporting an increased incidence of RA in AD patients31,32. However, the majority 
of these studies have used a small number of AD and RA patients and there is a lack of more recent, large-scale 
studies.
While it has been assumed that the protective effect of RA is due to the Nonsteroidal anti-inflammatory 
drugs (NSAIDs) that are used to treat it33, a recent randomized controlled trial (RCT), the Alzheimer’s Disease 
Anti-Inflammatory Prevention Trial (ADAPT), has shown that treatment with naproxen and celecoxib did not 
reduce AD incidence at 7 year follow up34. Additionally, a trial of the TNF-α inhibitor etanercept, another drug 
used to treat RA, caused no significant changes in cognition, behaviour or global function when recently tri-
alled in AD patients35. A systematic review and meta-analysis published by McGeer et al. in 199622 investigated 
arthritis itself, in addition to NSAID use, as a protective factor against AD. This study found that arthritis itself 
was associated with reduced AD incidence. The overall odds ratio, using arthritis as an AD risk factor, was 0.5622.
Here, we attempted to dissect the nature of the association between RA and AD by first employing a system-
atic literature review and an up-to-date meta-analysis of published epidemiological studies. As a fundamental 
limitation of observational data is that causation cannot automatically be inferred from an association between 
an exposure and a disease, as the association could be due to unobserved confounding or reverse causation36, 
Mendelian Randomization (MR) was then employed to formally investigate the causal association of RA with AD.
MR is an established tool for probing questions of causality in order to characterize the aetiology of dis-
ease36,37. It exploits the fact that genotypes are randomly assorted at meiosis, and are thus independent of con-
ventional confounding factors and the disease process. Therefore, genetic variants associated with intermediate 
traits can be used to provide an unconfounded estimate of the causal association between the intermediate trait 
and disease outcome, unaffected by reverse causality. This is akin to a “genetically randomized trial” and the 
genetic variants are known as Instrumental Variants (IVs). The following three assumptions are necessary for a 
genetic variant to be a valid IV: 1. the variant is predictive of the exposure; 2. the variant is independent of any 
confounding factors of the exposure—outcome association; 3. the variant is conditionally independent of the 
outcome given the exposure and the confounding factors. However, MR studies may be potentially confounded 
by pleiotropy (association of a genetic variant with more than one trait). Whereas vertical pleiotropy (where a 
genetic variant affects more than one point in the same causal pathway) does not necessarily breach the assump-
tions of MR, horizontal pleiotropy, where the variant affects more than one independent causal pathways, can 
lead to spurious conclusions about causality38. Nevertheless when multiple genetic variants are used as IVs there 
is a higher chance that pleiotropic effects might become balanced and causal inference is possible. Additionally, 
new methods that can give valid estimates in the presence of pleiotropy have been recently developed. We there-
fore also used, in addition to multi-SNP Inverse-Variance Weighted (IVW) MR (conventional MR), two recently 
developed methods; Egger-MR39 regression to test for unbalanced pleiotropy and provide a causal estimate of 
exposure on outcome in its presence, and weighted median MR40 which can give valid estimates even in the 
presence of horizontal pleiotropy if at least 50% of the weight comes from valid IVs. In the absence of horizontal 
pleiotropy, all three tests should be consistent.
The suggestion that it is RA itself that is protective, if found to be true, could contradict the current theory that 
AD pathogenesis is worsened by inflammatory processes in the periphery.
Results
Studies investigating Rheumatoid Arthritis as a Risk Factor for Alzheimer’s Disease. Ten stud-
ies were included in the review and meta-analysis of the literature and provided data on 6346 study subjects. 
Publication dates ranged from 1983–2002, and there were large variations in both study design and sample size. 
8 of the included studies were case control, while the remaining 2 were population-based studies (Supplementary 
Figure 1).
The characteristics of the 10 included studies that investigated RA as a risk factor for AD, and are therefore 
included in the meta-analysis, are summarised in Table 1. Studies that included “arthritis” as a risk factor without 
investigating RA specifically are indicated with an1 in the results table. Regarding the Lindsay et al. paper29, the 
Odds Ratio omitting decedents was used, as diagnosis of the type of dementia in these participants was not car-
ried out, and may have included other dementia subtypes such as vascular dementia.
8 studies showed RA as a negative risk factor AD, 6 of which were case control and 2, population-based23,24,26–30,41, 
of which 5 showed a significant risk reduction24,27–29,41. The remaining 2 showed that RA increased the risk of AD 
development31,32 (Table 1).
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Meta-Analysis of Studies. The results of the meta-analysis of the above 10 studies, including the weight 
assigned to each individual study, are shown below in Fig. 1. We performed a meta-analysis both separately for 
case-control and population studies and combining the two.
The meta-analysis results showed that, overall, RA did significantly reduce the risk of developing AD 
(OR = 0.60, 95% CI 0.46–0.77, p = 1.03 * 10−4). This is supported by both the analysis of the case control studies 
Case Control Studies
Study Year
Incidence of 
 RA (AD)
Incidence of 
RA (controls) Odds Ratio 95% CI Details of Study Population
NOS Total 
Score
Heyman et 
al.32 1983 16/40 (40%) 29/80 (36%) 1.17
1 0.54–2.56
Cases: 12 males and 28 females, all 
Caucasian. Mean age 60.8 at time of 
study admission.
6/9 (medium)Controls: Matched for age, sex and race
Study Location: Duke University 
Medical School, North Carolina, USA
French et al.26 1985 ?/78 ?/76 0.621 0.29–1.29
Cases: 78 Caucasian males.
7/9 (medium)
Controls: Matched for age, sex and 
race. Separate neighbourhood and 
hospital control groups.
Study Location: Veterans 
Administration Medical Centre, 
Minnesota, USA
Jenkinson et 
al.27 1989 2/96 (2%) 12/92 (13%) 0.14 0.03–0.65*
192 inpatients of a geriatric unit. All 65 
years or older.
5/9 (low)
Study Location: Hackney Hospital, 
London, UK
Graves et al.31 1990 8/130 (6.2%) 5/130 (3.8%) 1.18 0.35–3.91
Cases: 130 patients from a geriatric and 
family clinic
6/9 (medium)Controls: Matched where possible for age, sex, education, socioeconomic and 
marital status.
Study Location: Washington, USA
Broe et al.24 1990 92/170 (54%) 115/170 (68%) 0.561 0.36–0.87
Cases: Clinically diagnosed AD 
patients aged 52–96 years from a 
dementia clinic 7/9 (medium)
Controls: Matched for age and sex
Study Location: Sydney, Australia
Li et al.28 1992 4/70 (5.7%) 35/140 (25%) 0.161 0.05–0.51
Cases: Clinically diagnosed AD 
patients from psychiatric hospitals and 
neurology clinics
6/9 (medium)Controls: Age and sex matched 
neighbourhood controls.
Study Location: Beijing, China
Can. Health25 1994 104/201 (52%) 280/468 (60%) 0.541 0.36–0.81
Cases: AD subjects age 65 + from both 
institutions and the community
7/9 (medium)Controls: Neighbourhood controls
Study location: 36 cities across Canada
Brietner et 
al.23 1994 7/50 (14%) 11/50 (22%) 0.64
1 0.22–1.77
Co-twin control study on twins with 
AD onset separated by 3 or more years. 
Subjects found using the US National 
Academy of Sciences Research Council 
Registry
5/9 (low)
Study Location: USA
Population-based Studies
Study Year Incidence of RA in AD patients
Incidence of 
RA in controls Odds Ratio 95% CI Details of Study Population
NOS Total 
Score
Tyas et al.30 2001 19/35(54%) 360/651 (55%) 0.811 0.39–1.68
Longitudinal study based on randomly 
selected subjects of 65 or older who 
were initially cognitively intact. 9/9 (high)
Study Location: Manitoba: Canada
Lindsay et al.29 2002 90/167 (54%) 2013/3452 (58%) 0.61
1 0.43–0.87
Longitudinal study based on randomly 
selected subjects 65 or older from all 
10 Canadian provinces 9/9 (high)
Study Location: Nationwide across 
Canada
Table 1. Studies included in the meta-analysis. The study characteristics of the 8 case control and 2 population-
based studies included in the meta-analysis. 95% confidence intervals (CIs) and brief descriptions of the 
study populations, as well as the total NOS scale scores are included. *Calculated based on raw data. Data was 
assumed to be unadjusted. 1Study investigated ‘arthritis’ with no subtype for RA specifically.
www.nature.com/scientificreports/
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(OR = 0.563, 95% CI 0.39–0.812, p = 0.002) and the population-based studies (OR = 0.644, 95% CI 0.47–0.88, 
p = 0.006).
Assessment of Study Heterogeneity and evaluation of bias. Heterogeneity (I2) was low in the 
population-based studies, where it was estimated to be responsible for 0% of the variability. In the case control 
studies, it was responsible for an estimated 44.7% of variability. The overall I2 value was 33.2%.
Meta-regression analysis investigating study year (p = 0.894), study type (p = 0.651), quality of study 
(p = 0.661), age of participants (p = 0.830), percentage of RA in controls (p = 0.986) and whether RA specifically 
or arthritis was investigated (p = 0.840) indicated that that there was no significant change at the (log)OR of the 
outcome per unit increase of these covariates. For age, studies were assessed on whether or not the study included 
participants < 65.
Potential publication bias was explored graphically, producing the funnel plot shown in Additional File 2, 
which indicated a slight presence of asymmetry. Both Begg’s and Egger’s tests were therefore carried out to check 
for publication bias, and both showed that there was no evidence of bias (p = 0.929 and p = 0.668 respectively). 
Omitting the included studies one at a time indicated that no individual studies had any significant effect on the 
overall results.
The results of the meta-analysis therefore indicated a consistent protective association of RA and AD.
Mendelian Randomization Results. Although the overall results of the literature meta-analysis indicate 
that RA was associated with lower AD risk (OR = 0.60, 95% CI 0.46–0.77; p = 1.03 * 10−4), the summary causal 
estimate from conventional IVW MR showed no evidence to support a causal inverse association between RA 
and AD (OR = 1.018, 95% CI 0.98–1.06) (Table 2, Fig. 2). Similar results were observed when we used the Median 
Weighted (OR = 1.04, 95% CI 0.98–1.11), and the MR-Egger (OR = 1.05, 95%CI 0.94–1.17) estimators, and the 
MR-Egger regression suggested little evidence for unbalanced pleiotropy in the genetic instrument (intercept 
p = 0.51) (Table 2).
Finally, the “leave one out” results show that by omitting the included 62 SNPs one at a time, no individual 
genetic variants seem to have any significant effect on the overall results and after excluding 20% of the SNPs at 
a time (100000 times) 0.009% of the sensitivity coefficients layed outside the MR 95% CI highlighting that these 
results are not sensitive to SNP selection.
The MR analysis results therefore do not support a causal inverse association between RA and AD.
Figure 1. Literature Review meta-analysis results. The results of the meta-analysis, showing separate ORs for 
the case control and population-based studies, and then an overall OR, 95% CIs, study weight and heterogeneity 
are also shown.
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Discussion
We conducted a comprehensive review and up to date meta-analysis of studies investigating the association of RA 
with AD, followed by a MR analysis. The findings of these two types of analyses are contradictory (Fig. 3).
The overall results of the meta-analysis indicated that RA is associated with lower AD risk with an overall OR 
estimate of 0.60 (95% CI 0.46–0.77, p = 1.03 * 10−4), a finding very similar to one proposed by McGeer et al. in 
199622 in the earlier meta-analysis (OR = 0.556, 95% CI 0.44–0.70). This analysis therefore supports their work 
even with the inclusion of more recent population-based studies.
MR is a powerful tool to dissect causal relationships between an exposure and an outcome as it minimizes 
residual confounding by lifestyle factors, underlying ill-health, medication and selection bias present in obser-
vational studies. We performed three MR tests for causal estimation of RA on AD, two of which address hori-
zontal pleiotropy, and we performed additional sensitivity analyses. All Mendelian Randomization results were 
consistent with lack of association between RA and AD (OR = 1.018, 95% CI 0.98–1.06 for IVW, OR = 1.04, 95% 
CI 0.98–1.11 for Median Weighted OR = 1.05, 95%CI 0.94–1.17 for MR-Egger). We also found no evidence for 
unbalanced pleiotropy in the genetic instrument as indicated by the P-value of the MR-Egger intercept (p = 0.51), 
that provides additional confidence in the MR results.
Possible explanations for inconsistency between observational and MR findings. This was the 
first meta-analysis to investigate the effect on AD development of RA itself (irrespective of NSAID use) since 
McGeer et al. in 199622, and the only one to produce both separate and an overall OR from case control and 
population-based studies. A more recent meta-analyses included studies that included dementia (and not only 
AD) as well as results from non peer-reviewed journals42. Attempts were made to ensure lack of publication bias 
and an influence analysis was carried out to ensure that no one study was predominantly affected the results. 
Study year, study type, study quality, participant age, RA incidence in controls, and type of arthritis investigated 
were shown to have no significant effect on the results. Publication bias was also shown to be insignificant.
Heterogeneity and small number of studies included. However, this meta-analysis also had limi-
tations; owing to the limitations inherent to observational studies, heterogeneity was high due to differences in 
study design and population, despite taking factors that could have influenced it into consideration. Additionally, 
Analysis Method OR 95% CI P-value P-value (intercept)
Inverse-Variance 
Weighted (IVW) 1.018 0.98–1.06 0.354
Weighted Median 1.044 0.98–1.12 0.200
MR-Egger regression 1.052 0.94–1.17 0.363 0.513
Table 2. Results of the Mendelian Randomization analyses using different estimators. The intercept P-value can 
be interpreted as an estimate of the average (horizontal) pleiotropic effect across the genetic variants.
Figure 2. Bidirectional plot. Association of individual SNPs with RA and AD risk. The slopes each line 
represent the causal association for each method.
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6SCIENTIFIC RePORtS | 7: 12861  | DOI:10.1038/s41598-017-13168-8
there were a small number of studies included in the meta-analyses and no eligible studies after 2002. The low 
number of studies that met the inclusion criteria meant that all were included, regardless of their quality rat-
ing using the NOS. Ideally, only those of medium or high quality would be included. However, including the 
quality of the study as a covariate did not influence the results of the meta-analysis. Additionally, the majority 
of the included studies were case control and utilized small study samples; however, the results of the only two 
longitudinal population-based studies included also showed a relationship between RA and AD. Ideally, more 
population-based studies, which confer advantages such as larger sample size, a more representative sample 
and the ability to estimate the prevalence rate of risk factors in the target population, would be carried out and 
included in a meta-analysis on this topic. In population-based studies, cofounders to exposures and outcomes can 
also be evaluated, reducing bias43.
RA incidence and diagnosis. Another possible limitation of the meta-analysis was the large variation in 
RA incidence in controls given across the studies included in the meta-analysis analysis, ranging from 3.8–68%. 
While this could be due to a number of factors, including differing sources of controls, different sample sizes 
and different methods of diagnosing RA, it is worth considering as a factor that may have affected the results. 
In all but one of the studies (Jenkinson et al.27), the presence of RA was confirmed using structured interview 
or questionnaire. Ideally, it would be formally diagnosed by a clinician. Additionally, in studies that may have 
included osteoarthritis (“arthritis” was investigated), incidence in both cases and controls was higher than those 
that investigated RA alone, as expected. However, the variation of RA proportion in controls was not found to 
have a significant effect on the results. Additionally, incidence in cases correlated highly with that in controls 
(rho = 0.947, p = 1.0 * 10−4).
NSAID medication. The links between RA and AD have previously been described as due to a protective 
effect of NSAIDs. Both RA/arthritis and NSAID use were investigated as risk factors for AD in several studies 
included in this analysis. Most notably, Lindsay et al. found that both arthritis and NSAID use were protective 
when used in the same model alongside age, sex and education. Similar odds ratios (0.61 for arthritis and 0.65 for 
NSAID use) were generated for both of them, and their interaction was found to be non-significant (p = 0.10)29. 
Importantly, year of study may affect the treatment taken by included RA patients. Pharmacological therapies for 
RA have evolved over the past 25 years, with biologic response modifier treatments such as tumor necrosis factor 
alpha (TNF-α) inhibitors becoming available in the late 1990s44 – after most of the studies in this review were 
carried out. The antifolate drug methotrexate has become the initial treatment in many RA patients, and can be 
used as a monotherapy without the addition of NSAIDs or any other drugs44. The wide variety of RA treatments 
available today means that participants of earlier studies were probably more likely to be taking NSAIDs to treat 
their disease, while participants in later studies were possibly taking newer drugs (although NSAIDs are still used 
in RA treatment). This is particular relevant as this meta-analysis also suffered from lack of recent data, with 
only three included studies having been carried out since the year 2000. Additionally, of the studies that did not 
investigate NSAID use and arthritis separately, there is no way to confirm that the RA patients involved were not 
taking NSAIDs, meaning that this meta-analysis did not investigate RA incidence completely independent of 
NSAID use.
Figure 3. Meta-analyses and Mendelian Randomization analysis results for the association of RA with AD 
using different methods.
www.nature.com/scientificreports/
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Exclusion of relevant studies. Finally, we also excluded a number of studies that did not match our crite-
ria. A 1994 study by Myllykangas-Luosujarvi and Isomaki45 investigated the number of AD deaths in RA patients, 
compared to the entire Finnish population of age 55+. They found that 1.2% of RA patients (2/167) were diag-
nosed with AD at death, compared to 5.4% (227/4204) of the general population. A 1990 study by McGeer et al.33 
was also excluded; this study found that out of 923 patients in RA clinic, only 4 (0.4%) had AD, while 2/409 (0.5%) 
patients at AD clinic had RA. They compared this to the incidence of AD in the general population, considered in 
this study to be 2.7%. Recently, a large population study by Bauer et al.46 compared comorbidity including arthri-
tis in 9,139 elderly German individuals with dementia and 28,614 German age- and gender-matched control sub-
jects aged 65 years and older. They reported that the presence of arthritis was less frequent in dementia patients 
(OR = 0.82, 95% CI 0.76–0.88, p < 0.0001) although this association was less strong when only community-living 
individuals were examined (OR = 0.93, 95% CI 0.85–1.01, p = 0.102). However, this study was also excluded from 
our meta-analyses as it included patients with other types of dementia in addition to AD, such as vascular demen-
tia. Similarly, a more recent study investigating the association between several chronic inflammatory disorders, 
including RA and anti-inflammatory drugs, and all-cause dementia was also excluded from our meta-analysis47. 
This study showed that RA, amongst other inflammatory disorders, was associated with higher dementia risk 
only in treated patients, suggesting a modifiable role of drug therapy in the association between inflammation 
and dementia risk and it also reported that combined glucocorticoid and NSAID anti-inflammatory therapy was 
associated with lower risk of dementia among individuals with rheumatoid arthritis.
Finally, a recent study by Wallin et al.48 was the only population study to show an increased risk for AD 
and dementia amongst RA patients. However, this study was not included in our meta-analysis as it differed 
slightly from the others in that patients with mild cognitive impairment (MCI) were included in addition to AD 
patients and ordinal regression analysis results were reported48 instead of an OR of AD risk in RA compared 
to controls. When we repeated our meta-analysis including the ordinal regression results by Wallin et al.48, we 
observed no association between RA and AD for the population-based cohorts (OR = 1, 95% CI 0.45–2.20). 
However there was no overall difference to the overall meta-analysis result (OR = 0.67, 95%CI 0.48–0.93). With 
the exception therefore of the study by Wallin et al.48 these population-based studies also support the finding of 
the meta-analysis, although an overall OR comparable to that of the other studies was not produced due to vari-
ations in outcomes investigated.
MR strengths and limitations. The MR study has a number of obvious strengths. MR studies minimize 
bias inherent to observational studies such as confounding, regression dilution bias and reverse causation. 
However, MR studies are susceptible to bias from pleiotropy (association of genetic variants with more than one 
variable). Although vertical pleiotropy does not necessarily breach the assumptions of MR, horizontal pleiotropy 
could invalidate the MR assumption of the genetic variant only affecting the outcome conditional on the expo-
sure of interest, and potentially lead to biased causal estimates. Although the inclusion of multiple variants in MR 
analysis typically leads to increased statistical power it also results in the potential inclusion of pleiotropic genetic 
variants that are not valid IVs. To minimize horizontal pleiotropy we employed a weighted median estimator, 
which provides valid estimates even if 50% of the SNPs are not valid instruments and we employed MR-Egger 
regression to provide a test for unbalanced pleiotropy and a causal estimate of exposure on outcome in its pres-
ence. Our results using all three approaches were consistent, and the MR-Egger approach showed no evidence 
for unbalanced pleiotropy as indicated by intercept P-value. Even if MR-Egger results in loss of precision and 
power, our weighted median estimator results were also very similar to the IVW estimator providing additional 
confidence for these associations.
Another possible limitation to this MR study is the strength of our IV. Although we used 62 established RA 
SNPs, a score including more RA associated SNPs would have more power to detect a causal effect. To this end, we 
also repeated our analyses including SNPs associated with RA below genome-wide significance (total of 90 SNPs) 
but results were almost identical. Also, larger RA studies and meta-analyses are necessary in order to obtain 
stronger estimates with narrower confidence intervals. Finally, a number of additional analyses can be performed. 
For example, genetic variants can be categorized as relating to different disease mechanisms and separate MR 
estimates can be obtained using each category of variants37. For example, variants may be associated with RA by 
various mechanisms, such as chronic inflammation or immune dysregulation. A MR estimate constructed using 
variants associated with RA through chronic inflammation more closely represents the causal effect of inter-
vening on AD via inflammatory processes. Differences in the causal estimates using genetic variants associated 
with different mechanisms may be informative in understanding the aetiology of the disease, and may highlight 
specific mechanisms to prioritize for pharmacological intervention37.
Conclusion
Our study shows that although there seems to be an inverse association between incidence of RA and AD based 
on observational studies, MR analysis points to lack of a causal association. Examining the results from different 
methods that make different assumptions (IVW, Weighted Median, MR-Egger regression) provides a sensitivity 
analysis that either adds to or questions the robustness of a finding from a MR investigation. Here, the same 
result is reported across all methods, making the findings more plausible than if the methods gave contradic-
tory findings. The protective associations therefore observed in the observational studies could be due to bias 
inherent to observational studies such differential RA diagnosis, type of medication, small number of small 
size studies and selection bias. Further, well designed epidemiological studies and MR studies utilizing larger 
number of instruments and individuals could help draw more confident conclusions about the association of 
the two diseases.
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Methods
Systematic review. Systematic review search strategy. This review was carried out according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines49.
A search in October 2016 in a) MEDLINE and b) the Cochrane Library was carried out using the following 
search terms:
 1. Alzheimer*, dementia
 2. Rheumatoid arthritis, risk factor
 3. Incidence, prevalence, epidemiolog*
Combination of these terms (1 ∩ 2 ∩ 3), resulted in 7587 publications. Initial screening, which searched for 
publications relevant to the aims of this study, resulted in 16 publications being retained for evaluation. Their 
references were then searched for further relevant publications. Further screening according to the inclusion and 
exclusion criteria of this review (described below) resulted in 10 studies being included.
Inclusion Criteria. In order to be included in this review, studies were selected on the basis of their:
 1. Publication in English
 2. Publication in a peer-reviewed journal
 3. Full text availability
 4. Description of empirical research methods relevant to the aims of this review
 5. Comparison of the variable studied against a control group
 6. Investigation using RA as risk factor for AD
 7. The use of clinically diagnosed AD patients. Studies investigating other forms of dementia such as mild 
cognitive impairment (MCI) and vascular dementia were not included
The search process is summarised in Supplementary Figure 1.
Methodological Quality Assessment of Included Studies. Methodological quality assessment was carried out on 
each of the 12 included studies.
Studies were assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS). Using this scale, studies 
are assessed and awarded stars based on three domains: selection of study groups (maximum 4 stars), compara-
bility of study groups (maximum 2 stars), and ascertainment of exposure (maximum 3 stars). Slightly different 
versions of the scale are used for case control and population-based studies50.
A study with a score of 5 or less was considered of low quality, a score of 6–7 was considered medium quality, 
and a score or 8 or 9, high quality. The quality results are shown in Additional File 1. The use of the NOS resulted 
in 2 studies being deemed high quality, 6, of medium quality and 2 of low quality.
Meta-Analysis of Studies. Random-effects meta-analysis was performed using the “metan” command in STATA 
12 (StataCorp, College Station, TX, USA). Subgroup analysis was undertaken first, based on the type of study 
(case-control or population-based study), and then the results of these were combined to produce an overall odds 
ratio (OR).
Heterogeneity of studies was assessed using Cochran’s Q statistic to calculate Higgins and Thompson’s I2, a 
measure of the proportion of the total variability that can be explained by study heterogeneity. This was assessed 
first for each group of studies (case control and population-based), and then overall.
To estimate potential bias, the influence of individual studies on the summary effect estimate was first inves-
tigated using the “metainf ” command. This performs an influence analysis, in which the meta-analysis estimates 
are computed omitting one study at a time.
A funnel plot was used to visualize the variation of each study (using the “metafunel” command) followed by 
the Begg’s and Egger’s tests to investigate for funnel-plot asymmetry in meta-analysis (using the “metabias” com-
mand). If individual studies were found to have a large influence or introduce potential bias, analysis was repeated 
omitting them and results were compared.
Finally, the “metareg” command was used to perform meta-regression analysis to investigate the associations 
between the outcome of the study (AD or control) and study characteristics that may result in study heterogeneity 
such as study year, study type (case control or population-based study), study quality, age of study participants, 
incidence of RA in controls and whether arthritis or RA specifically was investigated.
8 case control and 2 population-based studies were included in the meta-analysis.
Mendelian Randomization (MR). Inverse-Variance Weighted (IVW) instrumental variable analyses. To 
investigate the causal associations between RA and AD we used summary statistics from the largest published RA 
Genome-wide Association (GWA) study and meta-analysis to date51 and summary data from the International 
Genomics of Alzheimer’s Project (IGAP)52, the largest GWA study and meta-analysis of AD reported to date. Of 
the 102 SNPs (101 loci) reported to be associated with RA by Okada et al.51, we excluded 2 SNPs located on the X 
chromosome as there were no available IGAP data2, 2 SNPs that were not directly genotyped or imputed, 7 SNPs 
that were not directly genotyped or imputed and which were additionally not associated with RA in individuals 
of European ancestry at genome-wide significance (p < 5 * 10−8) in combined meta-analyses and 1 SNP that was 
not directly genotyped or imputed and for which there was no available summary data in Okada et al. for indi-
viduals of European ancestry in combined meta-analyses. Of the 90 SNPs (89 loci) that were directly genotyped 
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or imputed, 28 SNPs were further excluded as they were not associated with RA at genome-wide significance 
(p < 5 * 10−8). We therefore used 62 SNPs (61 loci) that were directly genotyped or imputed and which were 
associated with RA in individuals of European ancestry at genome-wide significance (p < 5 * 10−8) in combined 
meta-analyses (Supplementary Table 2). We extracted the 62 summary SNP associations with AD from IGAP’s 
stage 1 results (17,008 AD cases and 37,154 controls) and selected as the “risk” allele that which was associated 
with increased RA risk.
The instrumental variable (IV) estimate from summary data was then obtained by summing the log Odds 
Ratio (log OR) of the individual logistic regression analyses of all 61 SNPs against AD and weighing this with the 
summary of the estimates of each SNP obtained from Okada et al.51 in an IVW meta-analysis (conventional MR) 
applying the Johnson formula described by Burgess et al.53. The delta method was used to approximate the stand-
ard error. We used only the first-order term from the delta expansion here; further terms were not considered 
because they did not affect estimates or standard errors.
Although the inclusion of multiple variants in a MR analysis typically leads to increased statistical power, 
it also presents challenges such as the potential inclusion of pleiotropic genetic variants that are not valid IVs. 
Whereas vertical pleiotropy does not necessarily breach the assumptions of MR, horizontal pleiotropy can lead 
to spurious conclusions about causality rendering the IVW estimator inefficient, especially when the precision of 
the individual estimates varies considerably.
MR-Egger instrumental variable analyses. To account for unmeasured horizontal pleiotropy, we performed 
MR-Egger analysis, an alternative summary data analysis method39 that tests for presence of, and accounts for, 
unbalanced pleiotropy by introducing a parameter for this bias. MR-Egger tests the hypothesis that the strength 
of the IV estimates of individual SNPs is symmetrically distributed around the point estimate. Symmetrical dis-
tribution suggests that pleiotropic effects, if present, are balanced and should not systematically bias the estimate 
of causal effect. Briefly, MR-Egger performs a weighted linear regression of the gene-outcome coefficients on the 
gene-exposure coefficients. The slope of this regression represents the causal effect estimate and the intercept can 
be interpreted as an estimate of the average (horizontal) pleiotropic effect across the genetic variants. MR-Egger 
regression replaces the second and third IV assumptions with the InSIDE assumption that states that the individ-
ual SNP effects on the exposure are independent of their pleiotropic effects on the outcome39.
Weighted Median Estimator instrumental variable analyses. We additionally used the weighted median estima-
tor, a method using summary data that offers protection against invalid instruments and provides a consistent 
estimate of causal effect if at least 50% of the weight comes from valid IVs40. We assume that no single IV contrib-
utes more than 50% of the weight, otherwise the 50% validity assumption is equivalent to assuming that this IV is 
valid. Analogously to the IVW method, we adopted the inverse of the variance of the ratio estimates as weights, 
as previously suggested40. The weighted median estimator has the advantage of retaining greater precision in the 
estimates compared to MR-Egger40.
Sensitivity analyses. A number of sensitivity analyses were finally performed to examine the stability of the sum-
mary causal estimate. Firstly, we performed a “leave one out” analysis to further investigate the possibility that 
the causal association was driven by a single SNP. We further we examined the stability of the summary causal 
estimate by repeatedly (100,000 times) excluding ~20% SNPs (12 SNPs), with replacement, from the instrument 
chosen at random in each cycle and collecting the resulting IV estimates. When more than 5% of the sensitivity 
coefficients lay outside the CI from the normal distribution of the estimate with complete data, there was evidence 
that the result was sensitive to SNP selection.
All MR analyses were performed in R 3.3.1.
Data availability. We have used publicly available data for this work.
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